Cancer therapy with β-lapachone

Current Cancer Drug Targets

Volumn 2, Issue 3, 2002, Pages 227-242

  Pardee, Arthur B ^a   Li, You Zhi ^a   Li, Chiang J ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BETA LAPACHONE; CASPASE; DICOUMAROL; DNA TOPOISOMERASE; NAPHTHOQUINONE; OXIDOREDUCTASE; OXIDOREDUCTASE INHIBITOR; PACLITAXEL; PROTEIN P53; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE);

APOPTOSIS; CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CELL DEATH; DNA REPAIR; DRUG MECHANISM; DRUG POTENTIATION; LETHALITY; MOUSE; NONHUMAN; OXIDATIVE STRESS; REVIEW; TUMOR GROWTH; X RAY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRAZIL; DRUG THERAPY, COMBINATION; HUMANS; NAPHTHOQUINONES; NEOPLASMS; PLANTS, MEDICINAL;

EID: 0036348011     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009023333854     Document Type: Review

References (144)

1. Quantitation of beta-lapachone and 3-hydroxy-beta-lapachone in human plasma samples by reversed-phase high performance liquid chromatography
2. β-lapachone-mediated apoptosis in human promyelocytic leukemia9 (HL-60) and human prostate cancer cells: A p53-independent response
3. Reaction of β-lapachone and related naphthoquinones with 2-mercaptoethanol: A biomimetic model of topoisomerase II poisoning by quinones
4. Comparison of antibacterial and antifungal activities of lapachol and beta-lapachone
5. Generation of superoxide anions and hydrogen peroxide from beta-lapachone in bacteria
6. β-lapachone, an inhibitor of oncornavirus reverse transcriptase and eukaryotic DNA polymerase-alpha. Inhibitory effect, thiol-dependence and specificity
7. β-lapachone: Synthesis of derivatives and activities in tumor models
8. Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication
9. The topoisomerase I inhibitors, camptothecin and beta-lapachone, induce apoptosis of human retinal pigment epithelial cells
10. Potential antipsoriatic agents: Lapacho compounds as potent inhibitors of HaCaT cell growth
11. Suppression of tumor necrosis factor-activated nuclear transcription factor-kappa B activator protein-1, c-Jun N-terminal kinase, and apoptosis by beta-lapachone
12. Inhibition of inducible nitric oxide synthase by beta-lapachone in rat alveolar macrophages and aorta
13. Cytotoxicity of β-lapachone, an naphthoquinone with possible therapeutic uses
14. In vitro and in vivo evaluation of the toxicity of 1,4-naphthoquinone and 1,2-naphthoquinone derivatives against Trypanosoma cruzi
15. Evaluation of the toxicity of 3-allyl-beta-lapachone against Trypanosoma cruzi bloodstream forms
16. Effect of quinones and nitrofurans on Trypanosoma mega and Crithidia fasciculata
17. Structural-antitumor activity relationships among quinone derivatives
18. Potent inhibition of tumor survival in vivo by beta-lapachone plus taxol: Combining drugs imposes different artificial checkpoints
19. Potent preclinical combination of taxol pus β-lapachone for human breast cancer
20. Induction of apoptosis by beta-lapachone in human prostate cancer cells
21. β-lapachone enhancement of lipid peroxidation and superoxide anion and hydrogen peroxide formation by sarcoma 180 ascites tumor cells
22. Topoisomerase-1 inhibitors for human malignant glioma: Differential modulation of p53, p21, bax and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and beta-lapachone
23. Effects of 1,2-naphthoquinones on human tumor cell growth and lack of cross-resistance with other anticancer agents
24. Potent induction of apoptosis by β-lapachone in human multiple myeloma cell lines and patient cells
25. Coordinate inhibition of DNA synthesis and thymidylate synthase activity following DNA damage and repair
26. Beta-lapachone greatly enhances MMS lethality to human fibroblasts
27. Potentiation of halogenated pyrimidine radiosensitizers in human carcinoma cells by beta-lapachone (3,4-dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran-5,6-dione), a novel DNA repair inhibitor
28. Inhibition of potentially lethal DNA damage repair in human tumor cells by beta-lapachone, an activator of topoisomerase I
29. Inhibition of radiation-induced neoplastic transformation by beta-lapachone
30. Cellular and molecular responses to topoisomerase I poisons. Exploiting synergy for improved radiotherapy
31. Effect of topoisomerase modulators on cisplatin cytotoxicity in human ovarian carcinoma cells
32. Toxicity of camptothecin to Chinese hamster cells containing 5-hydroxymethyl-2′-deoxyuridine in their DNA
33. NF-κB activation by camptothecin; a linkage between nuclear DNA damage and cytoplasmic signaling events
34. Induction of DNA topoisomerase II-mediated DNA cleavage by beta-lapachone and related naphthoquinones
35. The DNA damage response: Putting checkpoints in perspective
36. Induction of apoptosis in MCF-7:WS8 breast cancer cells by beta-lapachone
37. β-lapachone, a novel DNA topoisomerase I inhibitor with a mode of action different from camptothecin
38. β-lapachone induces cell cycle arrest and apoptosis in human colon cancer cells
39. β-lapachone induced cell death in human hepatoma (HepA2) cells
40. DNA damage and cytotoxicity induced by beta-lapachone: Relation to poly(ADP-ribose) polymerase inhibition
41. Release of mitochondrial cytochrome C in both apoptosis and necrosis induced by β-lapachone in human carcinoma cells
42. Molecular mechanism of quinone cytotoxicity
43. Immunochemical detection of quinol-thioether-derived protein adducts
44. Effects of beta-lapachone, a peroxide-generating quinone, on macromolecule synthesis and degradation in Trypanosoma cruzi
45. Lipid peroxidation and the generation of free radicals, superoxide anion, and hydrogen peroxide in beta-lapachone-treated Trypanosoma cruzi epimastigotes
46. Effect of beta-lapachone on superoxide anion and hydrogen peroxide production in Trypanosoma cruzi
47. Chemiluminescence enhancement by trypanocidal drugs and by inhibitors of antioxidant enzymes in Trypanosoma cruzi
48. Inhibition of microsomal lipid peroxidation and cytochrome P-450-catalyzed reactions by beta-lapachone and related naphthoquinones
49. Redox cycling of onaphthoquinones in trypanosomatids. Superoxide and hydrogen peroxide production
50. Anticarcinogenic potential of DNA-repair modulators
51. Postreatment exposure to camptotecin enhances the lethal effects of x-rays on radioresistant human malignant melanoma cells
52. Reduced sensitivity to camptothecin of topoisomerase I from a L5178Y mouse lymphoma subline sensitive to X-radiation
53. Differential induction of apoptosis in x-irradiated L5178Y sublines bearing p53 mutation
54. Monitoring and signaling of radation-induced damage in mammalian cells
55. Effect of specific enzyme inhibitors on replication, total genome DNA repair and on gene-specific DNA repair after UV irradiation in CHO cells
56. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: Demonstration of tumor-type specificity and implications for cancer chemotherapy
57. Correlations between the activities of DNA polymerase alpha and the glucocorticoid receptor
58. NAD(P)H:quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity
59. Apoptosis and androgen-independent mammary and prostate cell lines induced by topoisomerase inhibitors: Common pathways of gene regulation
60. Down regulation of topoisomerase I in mammalian cells following ionizing radiation
61. DNA topoismerases
62. Topoisomerase I poisons and suppressors as anticancer drugs
63. Induction of apoptosis in human retinoblastoma cells by topoisomerase inhibitors
64. Concetration and timing dependence of lethalty enhancement between topotecan, a topoisomerase I inhibitor, and ionizing radiation
65. Radiation lethality enhancement with 9-aminocamptothecin: Comparison to other topoisomerase I inhibitors
66. The production of chromosomal alterations by beta-lapachone, an activator of topoisomerase I
67. Degradation of topoisomerase I induced by topoisomerase I inhibitors is dependent on inhibitor structure but independent of cell death
68. Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomrase I: Evidence for cell cycle-independent toxicity
69. DNA fragmentation induced by protease activation in 53-null human leukemia HL60 cell undergoing apoptosis following treatment with the topoisomerase I inhibitor camptothecin: Cell free system studies
70. Complex response of breast epithelial cell lines to topoisomerase inhibitors
71. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin
72. Novel mechanisms of DNA topoisomerase 11 inhibition by pyranonaphthoquinone derivatives-eleutherin, alpha lapachone, and beta lapachone
73. Novel mechanism of cellular DNA topoisomerase II inhibition by the pyranonaphthoquinone derivatives alpha-lapachone and beta-lapachone
74. Calcium is a key signaling molecule in beta-lapachone-mediated cell death
75. The relative essentiality of the antioxidative function of coenzyme Q - The interactive role of DT-diaphorase
76. DT-diaphorase: Possible roles in cancer chemotherapy and carcinogenesis
77. Identification and characterization of x-ray-induced proteins in human cells
78. Immunohistochemical detection of NAD(P)H:quinone oxidoreductase in human lung and lung tumors
79. Potency of Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulfhdryl groups
80. Comparison of hepatic carcinogen initiation-promotion systems
81. The levels of quinone reductases, superoxide dismutase and glutathione-related enzymatic activities in dietylstilbestrol-induced carcinogenesis in the kidney of male Syrian golden hamsters
82. NAD(P)H: Quinone oxidoreductase 1 (DT-diaphorase) expression in normal and tumor tissues
83. DT-diaphorase and cytochrome B5 reductase in human lung and breast tumors
84. Activation of a cysteine protease in MCF-7 and T47D breast cancer cells during β-lapachone-mediated apoptosis
85. β-lapachone-induced apotosis in human prostate cancer cells: Involvment of nqo/xip3
86. Quinone reductase inhibitors block SAPK/JNL and NFkB pathways and potentiate apoptosis
87. Effects of modulation of tissue activities of DT-diaphorase on toxicity of 2,3-dimethyl-1,4-naphthoquinones to rats
88. Redox and addition chemistry of quinoid compounds and its biologial implications
89. Redox cycling of beta-lapachone and related o-naphthoquinones in the presence of dihydrolipoamide and oxygen
90. Characteristics of Ca2+ transport by Trypanosoma cruzi mitochondria in situ
91. Transport of calcium by mitochondria
92. The mitocondrial energy transition: Its molecular mechanism and role in reperfusion injury
93. Differential mechanisms of induction of the mitochondrial permeability transition by quinones of varying chemical reactivities
94. Inhibition of mitochondrial function in HL60 cells is associated with an increased apoptosis and expression of CD14
95. Signaling mechanisms and oxidative stress in apoptosis
96. Intracellular ATP, a switch in the decision between apotosis and necrosis
97. Mitochondria and apoptosis
98. Mitochondria and cell death. Mechanistic aspects and methodological issues
99. Cell type specific involvement of death receptor and mitocondrial pathways in drug-induced apotosis
100. A matter of life and death
101. Mitochondrial NADH-quinone oxidoreductase of the outer membrane is responsible for paraquat cytotoxicity in rat livers
102. Characterization and partial purification of microsomal NAD(P):quinone oxidoreductases
103. The enzymology of doxorubicin quinone reducution in tumour tissue
104. Activation of c-Jun NH2-terminal kinase and subsequent CPP32/Yama during topoisomerase inhibitor beta-lapachone-induced apoptosis through an oxidation-dependent pathway
105. Dysregulation of apoptosis in cancer
106. Tumor necrosis factor alpha induces BID cleavage and bypasses antiapoptotic signals in prostate cancer LNCaP cells
107. A role for mitochondrdial Bak in apoptotic response to anticancer drugs
108. Facile determination of homeoplastic mitochondrial DNA mutations in primary tumors and bodily fluids
109. Mitochondrial diseases in man and mouse
110. Disorders related to mitochondrial membranes: Pathology of the respiratory chain and neurodegeneration
111. Mitochondria harbouring mutant mtDNA - A cuckoo in the nest
112. Induction of CDK inhibitors (p21(WAF1) and p27(Kip1)) and Bak in the beta-lapachone-induced apoptosis of human prostate cancer cells
113. Bcl-2 protects against beta-lapachone-mediated caspase 3 activation and apoptosis in human myeloid leukemia (HL-60) cells
114. Dual function for poly(ADP-ribose) synthesis in response to DNA strand breakage
115. Poly (ADP-ribose) synthesis in cells undergoing apoptosis: An attempt to face death before PARP degradation
116. Characterization of poly (ADP-Ribose) polymerase from crithidia fasciculata: Enzyme inhibition by β-lapachone
117. Target to apoptosis: A hopeful weapon for prostate cancer
118. Apoptosis and cancer drug targeting
119. A model for p53-induced apoptosis
120. Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1
121. NF-κB - Ten years after
122. The nuclear factor kappa B (NF-kB); a potential therapeutic target for estrogen receptor negative breast cancers
123. NF-kappa B activation results in rapid inactivation of JNK in TNF alpha-treated ewing sarcoma cells: A mechanism for the anti-apoptotic effect of NF-kappa B
124. Predicting chemoresistance in human malignant glioma cells: The role of molecular genetic analyses
125. The univalent reduction of oxygen by reduced flavins and quinones
126. Unexpected genetic and structural relationships of a long-forgotten flavoenzyme to NAD(P)H:quinone reductase (DT-diaphorase)
127. Involvement of hydrogen peroxide in topoisomerase inhibitor beta-lapachone-induced apoptosis and differentiation in human leukemia cells
128. Comparative study of apoptosis and necrosis in HepG2 cells: Oxidant-induced caspase inactivation leads to necrosis
129. Reactive oxygen species from NAD(P)H:quinone oxidoreductase constitutively activate NF-KappaB in malignant melanoma cells
130. Effect of dyskinetoplastic agents on ultrastructure and oxidative phosphorylation in crithidia fasciculata
131. Selective cleavage of kinetoplast DNA minicircles promoted by antitrypanosomal drugs
132. Isolation of x-ray-inducible transcripts from radioresistant melanoma cells
133. A concomitant ATP-depleting stratagy makedly enhances antcancer agent activity
134. Proapoptotic Bcl-2 relative bim is required for certain apoptotic responses, leukocyte homeostasis and to preclude autoimmunity
135. Docetaxel: An update of its use in advanced breast cancer
136. Bioactive furanonaphthoquinones from crescentia cujete
137. Antibacterial and antifungal compounds from kigelia pinnata
138. Antifungal and antibacterial naphthoquinones from newbouldia laevis roots
139. Antitumor-promoting naphthoquinones from catalpa ovata
140. Cytotoxic constituents of the roots of ekmanianthe longiflora
141. Microbial transformations of natural antitumor agents: Conversion of lapachol to dehydro-alpha-lapachone by curvularia lunata
142. Chemical reactivity studies with naphthoquinones from tabebuia with anti-trypanosomal efficacy
143. Preparation and cytotoxicity toward cancer cells of mono(arylimino) derivatives of β-lapachone
144. Activity of some naphthoquinones on blood stream forms of Trypanosoma cruzi